RATING
2022-08-08 |
B-
|
Sell
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Strong Sell
|
|
Return On Asset: |
Strong Sell
|
|
DE: |
Neutral
|
|
P/E: |
Sell
|
|
Price To Book: |
Sell
|
|
QUARTER GROWTHS |
|
1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE 0 | sector: PE 0
|
PE RATIO: COMPANY / INDUSTRY |
N/A
|
Company: PE 0 | industry: PE 0
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 0.109 - 0.179
( +/- 24.29%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2017-09-15 | Mazur Leonard L | Buy | 40 000 | Options to Purchase Common Stock |
2017-09-15 | Holubiak Myron Z | Buy | 40 000 | Options to Purchase Common Stock |
2017-09-15 | Dutia Suren G | Buy | 10 000 | Options to Purchase Common Stock |
2017-09-15 | Kane William | Buy | 10 000 | Options to Purchase Common Stock |
2017-09-15 | Webb Carol | Buy | 10 000 | Options to Purchase Common Stock |
INSIDER POWER |
0.00
|
Last
36 transactions |
Buy:
31 960 177 | Sell:
5 683 279 |
Forecast:
01:40 - $-0.0060
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$0.144 (-3.93% )
|
Volume |
0.0054 mill
|
Avg. Vol. |
0 mill
|
% of Avg. Vol |
0 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For CTXRW
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.